Connection

Michael Hallek to Bendamustine Hydrochloride

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Bendamustine Hydrochloride.
Michael Hallek
Connection Strength
1.275
Bendamustine Hydrochloride
  1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.753
  2. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
    View in: PubMed
    Score: 0.193
  3. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
    View in: PubMed
    Score: 0.182
  4. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
    View in: PubMed
    Score: 0.147
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.